Core Insights - Cytek Biosciences, Inc. has been recognized as one of America's Growth Leaders of 2026 by TIME in partnership with Statista, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][14]. Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver innovative tools for laboratories [7]. - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [7]. Financial Performance - The inclusion in TIME's list signifies Cytek's strong financial foundation and sustained business expansion, reflecting its ability to deliver long-term value [2][5]. - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, indicating their significant impact on global research [4]. Innovation and Technology - Cytek's mission is to make high-parameter cell analysis more accessible and cost-effective, addressing urgent challenges in health and science, such as cancer research and vaccine development [3]. - The company's FSP technology sets a new standard in flow cytometry, enhancing the precision and sensitivity of cell analysis [3][7]. Market Position - Being named to the Growth Leaders list places Cytek among an elite group of companies demonstrating resilience and a forward-looking approach in a dynamic market [5].

Core Insights - Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District, reflecting its commitment to the EMEA region and enhancing service for customers [1][4] - The new site has increased the company's footprint by over 40% and includes a dedicated customer service and training center, providing hands-on training for researchers [2] - The success of Cytek's reagent business is a major driver for this expansion, with the company transitioning warehouse operations in-house to improve operational efficiency and quality control [3] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company's product offerings include various systems and technologies designed to enhance multiplexing capabilities and provide comprehensive solutions for researchers [5] - Cytek's products are primarily for research use, with certain systems available for clinical use in specific regions [6] Strategic Importance - Europe is identified as a key region for Cytek's global growth, and the new Amsterdam facility is expected to enhance the company's capabilities in delivering solutions and services across the EMEA region [4][15] - The expansion aims to support scientific understanding and accelerate data-driven decision-making, fostering innovation within the industry [4]

Core Insights - Cytek Biosciences reported a total revenue of $45.6 million for Q2 2025, reflecting a 2% decrease compared to Q2 2024, primarily due to lower product revenue in EMEA and APAC regions, although service revenue showed growth globally and in the U.S. [5][10] - The company launched the Cytek Aurora Evo system, which is expected to enhance the adoption of its solutions and strengthen its market position [3][10] - Cytek's total recurring revenue, which includes service and reagent revenues, grew by 16% year-over-year, accounting for 32% of the total revenue over the last 12 months [10] Financial Performance - GAAP gross profit for Q2 2025 was $23.9 million, a 6% decrease from Q2 2024, with a gross profit margin of 52% compared to 55% in the previous year [6][10] - Operating expenses increased by 2% to $34.5 million, with R&D expenses decreasing by 12% to $8.8 million, while general and administrative expenses rose by 16% to $13.5 million [7][8] - The net loss for Q2 2025 was $5.6 million, an improvement from a net loss of $10.4 million in Q2 2024 [8][10] Market Outlook - The company narrowed its 2025 revenue guidance to a range of $196 million to $205 million, indicating a potential growth of -2% to +2% compared to 2024 [12] - Cytek aims to expand its installed base globally and enhance recurring revenue through its service and reagent businesses, while focusing on innovation to redefine industry standards [4][10]

Core Viewpoint - Cytek Biosciences, Inc. will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, indicating its active engagement in the healthcare investment community [1]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that specializes in high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [3]. - The company offers a comprehensive suite of products including the Cytek Aurora™, Northern Lights™, and Cytek Orion™ systems, as well as flow cytometers and imaging products under the Amnis and Guava brands [3]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [3]. Upcoming Events - Cytek management is scheduled for a fireside chat on June 11 at 11:40 a.m. Pacific Time, which will be accessible via a live and archived webcast on the company's website [2].

Core Insights - Cytek Biosciences reported a total revenue of $41.5 million for Q1 2025, reflecting a 7.6% decrease compared to Q1 2024, primarily due to a slowdown in product sales in the US and EMEA regions, although this was partially offset by growth in the APAC region and strong service revenue globally [4][8] - The company experienced a gross profit of $20.2 million in Q1 2025, which is a 12% decrease from the previous year, resulting in a GAAP gross profit margin of 49% compared to 51% in Q1 2024 [5][20] - Operating expenses increased by 4.1% to $35.1 million, with general and administrative expenses rising significantly from $11.4 million in Q1 2024 to $12.9 million in Q1 2025 [6][7] - The net loss for Q1 2025 was $11.4 million, compared to a net loss of $6.2 million in Q1 2024, indicating a worsening financial position [7][20] - Cytek's cash and marketable securities totaled $265.6 million as of March 31, 2025, down from $277.9 million at the end of 2024, despite share repurchases of $10.6 million during the quarter [9][20] - The company has revised its full-year 2025 revenue guidance to a range of $196 million to $210 million, which represents a potential decline of 2% to growth of 5% compared to 2024 [10] Financial Performance - Total revenue for Q1 2025 was $41.5 million, with product revenue at $28.1 million and service revenue at $13.3 million [20] - Gross profit for the quarter was $20.2 million, leading to a GAAP gross margin of 49% [5][20] - Operating expenses were $35.1 million, with research and development expenses at $9.7 million and sales and marketing expenses remaining flat at $12.5 million [6][20] - The adjusted EBITDA loss for Q1 2025 was $3.3 million, compared to a loss of $0.7 million in Q1 2024 [8][20] Strategic Developments - Cytek expanded its installed base to 3,149 instruments, adding 115 units in Q1 2025, and commenced operations in Singapore to enhance manufacturing capacity [8] - The company launched the Cytek Muse Micro instrument, aimed at providing an affordable option for simplified flow cytometry [8] - Cytek repurchased $10.6 million of its common stock during the first quarter, indicating a commitment to returning value to shareholders [8]

Core Insights - Cytek Biosciences is committed to advancing cell analysis through its patented Full Spectrum Profiling™ (FSP) technology, which will be showcased at key industry events such as CYTO 2025 and IMMUNOLOGY2025 [1][2][5] Company Overview - Cytek Biosciences, Inc. (Nasdaq: CTKB) is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity tools [6][7] - The company’s FSP technology enhances multiplexing capabilities with precision and sensitivity, positioning it as a pioneer in spectral flow cytometry [6][2] Industry Events - At IMMUNOLOGY2025, Cytek will present its complete cell analysis solutions, including instruments, reagents, and software, aimed at advancing research and discovery [3][4] - The company will also host a workshop on in-depth characterization of mouse immune responses during the event [4] - CYTO 2025 will feature Cytek as a Platinum sponsor, where it will showcase technology designed to accelerate scientific discovery [4][5] Strategic Goals - Cytek aims to make flow cytometry technology more accessible and scalable, unlocking new opportunities in high-growth areas such as immunology, oncology, and cell therapy [2][5] - The company emphasizes its commitment to delivering innovative and flexible solutions to empower researchers and accelerate breakthroughs in scientific advancement [5]